Imaging services chain Medical Resources has made a number of moves to strengthen its management team. The company named Lawrence Ramaekers to its previously vacant post of CEO and has also begun a review of its related-party transactions in response to
Imaging services chain Medical Resources has made a number of moves to strengthen its management team. The company named Lawrence Ramaekers to its previously vacant post of CEO and has also begun a review of its related-party transactions in response to concerns from shareholders and members of senior management.
Ramaekers, who will serve as acting CEO, is a principal at management consulting firm Jay Alix & Associates and specializes in interim management assignments. He has previously worked as CEO at national restaurant chain Family Restaurants, and as COO of National Car Rental.
The investigation of the company's related-party transactions will focus principally on fees for investment banking, advisory, and other services paid to 712 Advisory Services, an affiliate of Medical Resources chairman Gary Siegler. In addition to assessing the manner by which the company considers related-party transactions, the review will examine the fairness of all such transactions and the adequacy of their disclosure. The review will also develop recommendations on what changes, if any, should be made to the company's procedures.
In the quarter ended September 30, 712 Advisory Services received around $1 million for services rendered involving six different acquisitions with an aggregate transaction value of approximately $33 million, according to Medical Resources. All earlier payments to 712 have previously been reported on a timely basis, according to the firm. Siegler and 712 believe that all of its financial advisory fees are and were proper, but will nevertheless abide by the findings of the independent review, according to the company.
Medical Resources has retained outside counsel to investigate the 712 transactions. A committee of directors formed by the board will initially oversee the review, although two new directors who will soon be added to the board will assume ultimate responsibility for the review.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.